Nebenwirkungen · Gazyvaro
Gazyvaro 1 000 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19
HOS-129912 · Präparat HOS-096817
The adverse drug reactions (ADRs) from clinical trials were identified during induction, maintenance and follow up for indolent Non-Hodgkin lymphoma (iNHL) including FL; treatment and follow up for CLL in the three pivotal clinical studies: • BO21004/CLL11 (N=781): Patients with previously untreated CLL • BO21223/GALLIUM (N=1390): Patients with previously untreated iNHL (86% of the patients had FL) • GAO4753g/GADOLIN (N=409): Patients with iNHL (81% of the patients had FL) who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T10:49:00Z · SHA-256 18e252f824981860d284b6a8d0590c4e67726398fe4cfebbac1cb10441aeb96a · Passage 1217ffe61746f811342735b3ca37d42ebda937c77a6fc437cb338e197530a631 · Zeichen 312–951 im Abschnitt